Nutraceutical Pathway

Anti-diabetic lead, PM 2040: PM2040 is an enriched fraction from the Ayurvedic drug Parinam. Parinam has shown efficacy equivalent to standard therapeutics in diabetic patients without any adverse events. PhytoMyco has isolated a fraction, PM2040 that is more potent in animal models and is chemically defined. PhytoMyco has exclusive IP rights and expects to bring PM2040 as AYUSH licensed drug to the Indian market in 18 months.

Perceived Benefits of PM2040 in Diabetic patients

• Hypoglycemic efficacy with no adverse side effects
• Managing Diabetes among the NIDP population becomes easier
• Orally available and lower cost of therapy

Anti-diabetic lead, PM 908: Though PM2040 is the primary focus, PhytoMyco’s back-up candidate PM 908 is also a potential anti-diabetic agent, that is an extract from a single herb. PM 908 has been chemically characterized by identifying the Marker compounds (using LC-MS and other dereplication databases) for QC production. PM908 has also shown to have lipid lowering activity in vitro which could be an added benefit in diabetes control. Importantly, PM908, in an animal model of diabetes, reduced serum glucose levels comparable to the clinical standard drug Glibenclamide. We have filed an Indian patent for PM908 as a hypoglycemic agent